Xarelto（利伐沙班）适应症

Rivaroxaban (Xarelto) is a small molecule oral anticoagulant jointly developed by Bayer and Johnson & Johnson. Rivaroxaban (Xarelto) received marketing approval in Canada and the European Union on September 15 and October 1, 2008, respectively. On July 1, 2011, the FDA approved rivaroxaban (Xarelto) for the prevention of deep vein thrombosis in patients undergoing knee or hip replacement surgery.

Indications of Rivaroxaban (Xarelto): 1. For the prevention of venous thrombosis (VTE) in adult patients undergoing elective hip or knee replacement surgery. 2. Used to treat venous thrombosis (DVT) in adults and reduce the risk of DVT recurrence and pulmonary embolism (PE) after acute DVT. 3. For use in adult patients with nonvalvular atrial fibrillation who have one or more risk factors (e.g., congestive heart failure, hypertension, age ≥75 years, diabetes, history of stroke or transient ischemic attack) to reduce the risk of stroke and systemic embolism. 

Rivaroxaban (Xarelto) is an oral, bioavailable factor Xa inhibitor. Rivaroxaban (Xarelto) selectively blocks the active site of factor Xa and does not require cofactors (such as antithrombin III) to exert activity. Factor X is activated into factor Xa (FXa) through endogenous and exogenous pathways, which plays an important role in the coagulation cascade. Rivaroxaban (Xarelto, Xarelto) inhibits the activity of factor Xa in a dose-dependent manner in humans. Prothrombin time (PT), activated partial thromboplastin time (aPTT) measured with Neoplastin® reagent and HepTest® heparin quantitative test show a dose-dependent prolongation. Anti-factor Xa activity is also affected by rivaroxaban (Xarelto, Xarelto).